Year: 2017
Type: review
Abstract: (DSM), Fifth Edition, the specifier of depressive episode with atypical feature is present for both diagnostic groups, that is, depressive disorders and bipolar and related disorders. This specifier includes mood reactivity, hyperphagia, hypersomnia, leaden paralysis, and interpersonal rejection sensitivity. Prevalence rates of AD are variable, depending on the criteria, methodology, and settings. The results of epidemiological studies using DSM criteria suggest that 15%-29% of depressed patients have AD, and the results of clinical studies point to a prevalence of 18%-36%. A relationship of AD with bipolar depression, seasonal depression, and obesity has also been postulated. Pathogenic research has been mostly focused on distinguishing AD from melancholic depression. The differences have been found in biochemical studies in the areas of hypothalamic-pituitary-adrenal axis, inflammatory markers, and the leptin system, although the results obtained are frequently controversial. A number of findings concerning such differences have also been obtained using neuroimaging and neurophysiological and neuropsychological methods. An initial concept of AD as a preferentially monoamine oxidase inhibitor-responsive depression, although confirmed in some further studies, is of limited use nowadays. Currently, despite numerous drug trials, there are no comprehensive treatment guidelines for AD. We finalize the article by describing the future research perspectives for the definition, neurobiology, and treatment. A better specification of diagnostic criteria and description of clinical picture, a genome-wide association study of AD, and establishing updated treatment recommendations for this clinical phenomenon should be the priorities for the coming years.
DOI: 10.2147/ndt.s147317
Authors: Dorota Łojko, Janusz Rybakowski
Institution: Poznan University of Medical Sciences
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: atypical depression, bipolar depression, seasonal affective disorder, obesity, endogenous depression, mood reactivity, hyperphagia, hypersomnia, hypothalamic-pituitary-adrenal axis, inflammatory markers, leptin, monoamine oxidase inhibitors, depression treatment, genome-wide association study, diagnostic criteria
Open Access status: gold
Estimated APC paid: $2,836
OpenAlex ID: W2755141916
